Inactive Instrument

SANOCHEMIA Pharmazeutika AG

SAC

AT0000776307

SANOCHEMIA Pharmazeutika AG announced that it has received €6 million in funding from bew Beteiligungs GmbH

March 12, 2020

On March 13, 2020, SANOCHEMIA Pharmazeutika AG (XTRA:SAC) clsoed the transaction. The transaction has been approved by the shareholders of the company at the extraordinary shareholder meeting.

Latest news about SANOCHEMIA Pharmazeutika AG

EOSS Technology GmbH, Wirtschaft Burgenland GmbH – WiBuG and b·e·imaging·GmbH acquired SANOCHEMIA Pharmazeutika AG from bew Beteiligungs GmbH and other shareholders.	20-04-14	CI
SANOCHEMIA Pharmazeutika AG announced that it has received €6 million in funding from bew Beteiligungs GmbH	20-03-12	CI
Bew Beteiligungs GmbH acquired an unknown stake in SANOCHEMIA Pharmazeutika AG from Inphasearch AG.	20-03-09	CI
SANOCHEMIA Pharmazeutika AG announced that it expects to receive €6 million in funding from bew Beteiligungs GmbH	20-02-16	CI
SANOCHEMIA Pharmazeutika AG Announces Positive Topline Results from Phase 2 Star Study of Tolperisone in Acute Muscle Spasms of the Back in the U.S	19-09-24	CI
Sanochemia Pharmazeutika Ag Names Timo Bender as CEO, Effective February 1, 2019	19-01-25	CI
B·e·imaging·GmbH acquired 14.5% stake in SANOCHEMIA Pharmazeutika AG from Inphasearch AG.	19-01-17	CI
SANOCHEMIA Pharmazeutika AG Announces Board Changes	18-09-06	CI
Sanochemia Pharmazeutika Ag Reports Earnings Results for the Six Months of the Year 2018	18-05-23	CI
Sanochemia Pharmazeutika AG Announces Sales Results for the First Quarter of Fiscal 2017; Provides Earnings Guidance for the Full Year of Fiscal 2017	17-02-22	CI
Invesa AG and Inphasearch AG cancelled the acquisition of 34.9% stake in Sanochemia Pharmazeutika AG from Sanochemia Ltd.	17-02-21	CI
Sanochemia Announces Earnings Results for the Full Year of Fiscal 2016	16-05-31	CI
Invesa AG and Inphasearch AG agreed to acquire 34.9% stake in Sanochemia Pharmazeutika AG from Sanochemia Ltd.	16-02-21	CI
Sanochemia Extends Contracts with Janssen N.V	15-11-16	CI
Sanochemia Reports Preliminary Earnings Results for the Fiscal Year 2013	13-12-10	CI
Link Healthcare Obtains Extensive Regional Rights to Secrelux from Sanochemia Pharmazeutika AG	13-05-14	CI
Sanochemia Pharmazeutika AG's Equity Buyback has expired	12-09-22	CI

Chart SANOCHEMIA Pharmazeutika AG

Duration

Period

More charts

Sanochemia Pharmazeutika AG is an Austrian pharmaceutical company focused on the development and manufacture of drugs and diagnostics in neurodegeneration, pain and oncology areas, among others, as well as diagnostics based on contrast media. It operates through three main business divisions and the Production Division, which acts on behalf of those business divisions or on a contract manufacturing basis. The Production Division is engaged in the synthesis of active pharmaceutical substances (APIs), drug formulation and pharmaceutical production. The Human Pharmaceuticals Division is primarily responsible for the Company's diagnostic activities. The Research and Development Division is responsible for the Company's development activities. The Veterinary Pharmaceuticals Division comprises a portfolio of veterinary medical product and distribution channels in the CEE markets, Middle East and South-East Asia. The Company's shareholders are Inphasearch AG and Invesa AG, among others.

Sector

Pharmaceuticals

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
INDIVIOR PLC	+18.82%	2.38B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B

Specialty & Advanced Pharmaceuticals